Biocartis Idylla GeneFusion Assay

Biocartis has launched its Idylla GeneFusion Assay. The firm said the research-use-only test analyzes a wide range of biomarkers covering all gene fusions considered to be relevant in cancer research, including ALK, ROS1, RET, NTRK1/2/3 fusions, and MET exon 14 skipping mutations. Biocartis' test, which produces results within three hours, is the first formalin-fixed, paraffin-embedded RNA-based assay on Biocartis' Idylla platform.